Holen Sie sich die Stockscreener-App
28.40
2.49%
0.69
Vorhandelsmarkt:
28.87
0.47
+1.65%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ALKS?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$27.71
Offen:
$27.39
24-Stunden-Volumen:
3.00M
Relative Volume:
1.47
Marktkapitalisierung:
$4.73B
Einnahmen:
$1.48B
Nettoeinkommen (Verlust:
$241.66M
KGV:
19.83
EPS:
1.4325
Netto-Cashflow:
$480.33M
1W Leistung:
+2.71%
1M Leistung:
-14.94%
6M Leistung:
+2.12%
1J Leistung:
-18.37%
1-Tages-Spanne:
$27.31
$28.52
1-Wochen-Bereich:
$27.00
$28.89
52-Wochen-Spanne:
$25.16
$36.32
Alkermes Plc Stock (ALKS) Company Profile
Firmenname
Alkermes Plc
Sektor
Telefon
00-353-1-772-8000
Adresse
CONNAUGHT HOUSE, DUBLIN 4
Compare ALKS vs TAK, ZTS, HLN, TEVA, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALKS
Alkermes Plc
|
28.40 | 4.73B | 1.48B | 241.66M | 480.33M | 1.4325 |
TAK
Takeda Pharmaceutical Co Adr
|
18.04 | 56.99B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
115.93 | 48.94B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.70 | 43.30B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.14 | 33.94B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
531.82 | 23.31B | 3.18B | 1.33B | 1.04B | 27.90 |
Alkermes Plc Stock (ALKS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-24 | Eingeleitet | Wolfe Research | Outperform |
| 2025-11-11 | Eingeleitet | Truist | Buy |
| 2025-09-26 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-09-03 | Eingeleitet | Wells Fargo | Overweight |
| 2025-07-15 | Eingeleitet | Goldman | Buy |
| 2025-06-17 | Hochstufung | UBS | Neutral → Buy |
| 2025-05-28 | Eingeleitet | Needham | Buy |
| 2025-03-13 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2025-03-04 | Hochstufung | UBS | Sell → Neutral |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Buy |
| 2024-11-05 | Hochstufung | Stifel | Hold → Buy |
| 2024-06-17 | Eingeleitet | TD Cowen | Buy |
| 2024-03-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-02-20 | Herabstufung | UBS | Neutral → Sell |
| 2023-11-20 | Fortgesetzt | JP Morgan | Neutral |
| 2023-10-24 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-10-17 | Eingeleitet | UBS | Neutral |
| 2022-11-03 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-14 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-08-16 | Eingeleitet | Piper Sandler | Neutral |
| 2022-04-22 | Fortgesetzt | Goldman | Buy |
| 2022-04-20 | Eingeleitet | Goldman | Buy |
| 2022-01-27 | Hochstufung | Cantor Fitzgerald | Hold → Overweight |
| 2021-12-01 | Eingeleitet | Citigroup | Neutral |
| 2021-10-07 | Hochstufung | Jefferies | Hold → Buy |
| 2021-09-02 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2020-10-15 | Hochstufung | Mizuho | Neutral → Buy |
| 2020-07-30 | Herabstufung | Goldman | Neutral → Sell |
| 2020-02-14 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2020-02-14 | Bestätigt | H.C. Wainwright | Neutral |
| 2020-02-14 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-02-06 | Eingeleitet | Mizuho | Neutral |
| 2020-01-31 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2019-09-05 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2019-07-15 | Hochstufung | Goldman | Sell → Neutral |
| 2019-05-31 | Eingeleitet | H.C. Wainwright | Neutral |
| 2019-05-01 | Herabstufung | Citigroup | Buy → Neutral |
| 2018-12-19 | Herabstufung | Goldman | Neutral → Sell |
| 2018-12-14 | Eingeleitet | Wolfe Research | Underperform |
| 2018-12-13 | Herabstufung | Credit Suisse | Outperform → Underperform |
| 2018-11-05 | Eingeleitet | Piper Jaffray | Neutral |
| 2018-08-07 | Eingeleitet | Stifel | Hold |
| 2018-06-21 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2018-06-06 | Eingeleitet | B. Riley FBR, Inc. | Buy |
| 2018-05-16 | Hochstufung | Citigroup | Neutral → Buy |
| 2018-05-11 | Eingeleitet | BofA/Merrill | Buy |
Alle ansehen
Alkermes Plc Aktie (ALKS) Neueste Nachrichten
Alkermes (ALKS): Piper Sandler Lowers Price Target, Maintains Ov - GuruFocus
Piper Sandler Issues Pessimistic Forecast for Alkermes (NASDAQ:ALKS) Stock Price - MarketBeat
Alkermes announces inaugural Alkermes Pathways APN Research Awards™ program - MSN
Alkermes plc stock launches inaugural research awards program amid biotech innovation push - AD HOC NEWS
If You Invested $1,000 in Alkermes Plc (ALKS) - Stock Titan
Alkermes shares rise after revenue beat and upbeat outlook offsets earnings miss - MSN
Big Picture: Can Alkermes plc stock outperform in a bear marketMarket Movers & Expert Approved Trade Ideas - baoquankhu1.vn
Alkermes Q4 2025 earnings preview - MSN
Alkermes outlines $1.73B–$1.84B 2026 revenue target as Avadel acquisition expands commercial reach - MSN
Alkermes plc (ALKS) Latest Stock News & Headlines - Yahoo Finance
Alkermes CEO Pops Calls 2026 a “Really Exciting Year” as Orexin Agonists Near Narcolepsy Launch - MarketBeat
Layoff Watch: Does Alkermes plc offer margin of safety2026 Volatility Report & Consistent Growth Equity Picks - baoquankhu1.vn
Holocene Advisors LP Cuts Holdings in Alkermes plc $ALKS - MarketBeat
Alkermes appoints new CFO - MSN
How Alkermes Plc (ALKS) Affects Rotational Strategy Timing - Stock Traders Daily
ALKS Stock Price, Quote & Chart | ALKERMES PLC (NASDAQ:ALKS) - ChartMill
Farallon Capital Management LLC Has $624,000 Stock Holdings in Alkermes plc $ALKS - MarketBeat
Alkermes plc Stock (ISIN: IE00B56GVS15) Under Pressure After Avadel Acquisition—Wells Fargo Raises - AD HOC NEWS
Alkermes plc $ALKS is Commodore Capital LP's 7th Largest Position - MarketBeat
Baker BROS. Advisors LP Boosts Holdings in Alkermes plc $ALKS - MarketBeat
Wolfe Research initiates coverage of Alkermes (ALKS) with outperform recommendation - MSN
Avoro Capital Advisors LLC Trims Position in Alkermes plc $ALKS - MarketBeat
Is Alkermes (ALKS) Pricing In Its Potential After Recent Share Price Weakness - Yahoo Finance
Market Outlook: Will Alkermes plc outperform its industry peers2026 Summary & Long-Term Growth Plans - baoquankhu1.vn
Victory Capital Management Inc. Has $10.33 Million Stock Position in Alkermes plc $ALKS - MarketBeat
Alkermes Announces Inaugural Alkermes Pathways APN Research Awards™ Program - The Joplin Globe
Opioid Use Disorder Market Booming with Rapid Growth Through 2033 | Indivior PLC • Alkermes • Orexo AB - openPR.com
Alkermes to Present at the Stifel 2026 Virtual CNS Forum - BioSpace
ALKS Technical Analysis & Stock Price Forecast - Intellectia AI
Citigroup Inc. Sells 121,945 Shares of Alkermes plc $ALKS - MarketBeat
Is Alkermes’ Slower Q4 and CEO Transition Reshaping Its Orexin Strategy and Investment Case (ALKS)? - simplywall.st
Rhenman & Partners Asset Management AB Buys 55,000 Shares of Alkermes plc $ALKS - MarketBeat
Neuberger Berman Group LLC Has $4.58 Million Holdings in Alkermes plc $ALKS - MarketBeat
Why analysts are rating Alkermes (ALKS) a buy - MSN
Alkermes Advances ALKS 2680 Into Phase 3 for Narcolepsy Type 1: What Investors Should Watch - TipRanks
Alkermes announces CEO succession plan - MSN
Alkermes plc (NASDAQ:ALKS) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Avadel Pharmaceuticals Shares Climb on $2.1 Billion Acquisition by Alkermes - MSN
(ALKS) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Race For Avadel Heats Up: Alkermes Raises Offer To Secure $2.37B Deal After Lundbeck Challenge - Stocktwits
Alkermes (NASDAQ:ALKS) EVP Sells $59,575.86 in Stock - MarketBeat
Craig Hopkinson Sells 9,000 Shares of Alkermes (NASDAQ:ALKS) Stock - MarketBeat
Christian Todd Nichols Sells 6,000 Shares of Alkermes (NASDAQ:ALKS) Stock - MarketBeat
Alkermes (ALKS) CCO granted options and RSUs, sells 6,000 shares at $30 - Stock Titan
TD Asset Management Inc Sells 91,772 Shares of Alkermes plc $ALKS - MarketBeat
2,034-share Rule 144 sale by Alkermes insider (NASDAQ: ALKS) - Stock Titan
ALKS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Celebrating LGBTQIA+ Mental Health Trailblazers - CSRwire
Alkermes Reports 2025 Financials, Advances Narcolepsy Pipeline, Announces CEO Succession - Sleep Review
Alkermes Pivots Deeper Into Sleep Medicine After Avadel Deal, Details Orexin Phase 3 at TD Cowen - Yahoo Finance
Alkermes (NASDAQ: ALKS) insider sells common stock via Form 144 - Stock Titan
Finanzdaten der Alkermes Plc-Aktie (ALKS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.75%
1.88%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):